Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-09-04, Stock:LLY, The news for the past five days is as follows:
2018-08-27: NEWS1: All-Time highs: 6 stocks to buy.NEWS2: Lilly to Participate in Morgan Stanley Global Healthcare Conference.NEWS3: Rimidi Announces Addition of Jim Clifford as Vice President of Strategic Sales.NEWS4: Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events.NEWS5: Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events.NEWS6: Is Eli Lilly (LLY) a High-Growth Dividend Stock?.NEWS7: Is Eli Lilly (LLY) a High-Growth Dividend Stock?.NEWS8: 5 Reasons Why You Should Add Lilly Stock to Your Portfolio.NEWS9: 5 Reasons Why You Should Add Lilly Stock to Your Portfolio.NEWS10: Is Eli Lilly (LLY) a High-Growth Dividend Stock?.NEWS11: 5 Reasons Why You Should Add Lilly Stock to Your Portfolio.
2018-08-28: NEWS1: Novartis’s Quarterly Revenue Trend in Q2 2018.NEWS2: 25 Dividend Stocks That Analysts Love the Most.NEWS3: Pfizer's Tafamidis Fails to Impress in Cardiomyopathy Study.NEWS4: Pfizer's Tafamidis Fails to Impress in Cardiomyopathy Study.NEWS5: Novartis’s Valuation in August.NEWS6: Pfizer&apos;s Tafamidis Fails to Impress in Cardiomyopathy Study.
2018-08-29: NEWS1: 25 Dividend Stocks That Analysts Love the Most.NEWS2: 25 Dividend Stocks That Analysts Love the Most.NEWS3: Novartis' Tafinlar/Mekinist Combo Gets EU Nod for 3rd Disease.NEWS4: Novartis' Tafinlar/Mekinist Combo Gets EU Nod for 3rd Disease.
2018-08-30: NEWS1: Anne White Promoted to President of Lilly Oncology.NEWS2: Pfizer’s Stock Performance in August.NEWS3: AstraZeneca (AZN) Gets EU Nod for New Formulation of Bydureon.NEWS4: AstraZeneca (AZN) Gets EU Nod for New Formulation of Bydureon.NEWS5: Estimates and Recommendations for Novartis in August.
2018-08-31: NEWS1: How Eli Lilly’s Business Segments Performed in Q2 2018.NEWS2: Glaxo's Asthma Drug Gets EU Nod for Pediatric Population.NEWS3: Glaxo's Asthma Drug Gets EU Nod for Pediatric Population.NEWS4: Analyzing Eli Lilly’s Q2 2018 Revenue Trend.NEWS5: Glaxo&apos;s Asthma Drug Gets EU Nod for Pediatric Population.NEWS6: Eli Lilly’s Valuation on August 30.NEWS7: Biotech Stocks Facing FDA Decision In September.NEWS8: Biotech Stocks Facing FDA Decision In September.

Answer: Decrease